Neurodegenerative Diseases

194 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Neurodegenerative Diseases
Treatment and conditionWhere it standsTrials
[F-18]Flornaptitril for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
1 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
120 milligrams of ENERGI-F705 Tablets for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
3 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
40 Hz sound stimulation for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
40 Hz Synchronous Audio-Visual Stimulation for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
60 milligrams of ENERGI-F705 Tablets for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
7 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
AADvac1 for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aav-gad for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-1001 Gene Therapy for huntington diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-1005 for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Activa PC+S Neurostimulator for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AD04 for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AD5-NCOV for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Adaptive (Closed Loop) DBS + Intermittent Open Loop DBS + Open Loop DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive (Closed Loop) DBS + Open Loop DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
Adaptive DBS (Activa PC+S Neurostimulator) + Continuous DBS (Activa PC+S Neurostimulator) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive DBS (aDBS) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive DBS delivered through AlphaDBS IPG System for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
adaptive deep brain stimulation + conventional deep brain stimulation for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
aDBS-Extended (Medtronic Percept™) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Administer Leqemi 10 mg/kg, every two weeks. for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aducanumab for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)4
Ambroxol for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ambroxol hydrochloride for lewy body diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Apitegromab for spinal muscular atrophies of childhoodPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
apomorphine infusion for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ATTN201 Focused Ultrasound to the CMN for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atuzaginstat for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Audiovisual stimulation VR system for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
autologous dopaminergic cell implantation for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous midbrain dopamine neurons for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BBB opening for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BIIB122 for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BIIB122 225 mg for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blood Brain Barrier (BBB) Disruption for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Buntanetap for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Buntanetap tartrate for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
CapeOX + bevacizumab + PD-1 Inhibitors + SBRT for spinocerebellar degenerationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cervical Lymphatic Microsurgery for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Closed-loop stimulation + GPi alone + STN + GPi + STN alone for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Combined metabolic activators for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Communication Bridge™ for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for corticobasal degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for multiple system atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CVN424 150 mg for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
CVN424 75 mg for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
DC-LVA treatment plus usual care for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Brain Stimulation, DBS for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Deep cervical lymph node to venous bypass (DCLNV-BP) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep cervical lymphatic-venous anastomosis for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep cervical lymphatic-venous anastomosis, LVA for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphaticovenous Anastomosis(DLVA) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphaticovenous Anastomosis(DLVA) for lewy body diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphaticovenous Anastomosis(DLVA) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical lymphatlc-Venous Anastomosis Surgery for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Deep cervical lymphovenous anastomosis (LVA) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphovenous Anastomosis + Routine Treatment for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Device-only fitting for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dexmedetomidine hydrochloride for dysautonomia, familialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diet + Exercise + Meditation for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)10
Donanemab for lewy body diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab + 2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy- for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab + Dexamethasone for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab + Nivegacetor for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DSP-1083 implantation for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Emestedastat for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Etanercept for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ExAblate 4000 Type 2.1 for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exenatide for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
Facilitate tDCS + CR for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fasudil for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FLORTAUCIPIR F-18 for neurodegenerative diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FLUOROETHOXYBENZOVESAMICOL F-18 for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Focused Transcranial Ultrasound for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Focused Transcranial Ultrasound for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Gam-COVID-Vac for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GammaSense Stimulation device for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Gantenerumab for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
GC101 for muscular atrophy, spinalPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GENUS device (Active Settings) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GV-971 for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
GV-971 + MEMANTINE for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High doses of Thiamine y Biotin for huntington diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High-Intensity Aerobic Exercise (AE) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
human Mesenchymal Stem Cells for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
intermittent theta burst stimulation (iTBS) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
intra-striatal rAAV5-miHTT for huntington diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
IPILIMUMAB + SINTILIMAB + Cetuximab + DABRAFENIB for spinocerebellar degenerationsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
JNJ-64042056 for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ketamine for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lecanemab for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
LECANEMAB + Etalanetug for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lifus for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lixisenatide for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
low intensity focused ultrasound (LIFU) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LY-2599666 for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LY3002813 for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3002813-IV for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3002813-SC for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3884961 + Sirolimus + Methylprednisolone for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Matching Placebo (E2814) + LECANEMAB for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Memantine for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Metformin for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mevidalen for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MK-1167 for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Moderate doses of Thiamine y Biotin for huntington diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Modified deep cervical Lymphatic-Venous Anastomosis for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Modified deep cervical Lymphatic-Venous Anastomosis for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MR guided low intensity focused ultrasound for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
NanoLithium® NP03 for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nicotinamide Riboside (NR) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nivegacetor for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NMS-01 for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
OAV101 for bulbo-spinal atrophy, x-linkedPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Obicetrapib 10 mg for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Onasemnogene abeparvovec for bulbo-spinal atrophy, x-linkedPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onasemnogene abeparvovec for muscular atrophy, spinalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Onasemnogene abeparvovec for spinal muscular atrophies of childhoodPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
PBT-434 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PEMBROLIZUMAB + Porustobart for spinocerebellar degenerationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Percept™ PC and Percept RC with Adaptive DBS (aDBS™) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 high dose (15 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 low dose (1 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 middle dose 1 (3 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 middle dose 2 (7 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + ADUCANUMAB for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)4
Placebo + Donanemab for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + SRP-1005 for huntington diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + TAVAPADON + TRIMETHOBENZAMIDE HYDROCHLORIDE for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prasinezumab for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Psilocybin for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Psilocybin + PIMAVANSERIN for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Receive tDCS+CR for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
REPAIR Sleep for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Risdiplam for muscular atrophy, spinalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
ROC-101 for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semagludtide for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Service-only Fitting for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Simufilam for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
SKG0201 Injection for spinal muscular atrophies of childhoodPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sodium oligo-mannurarate 600mg for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sodium oligo-mannurarate 900mg for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sodium Oligomannate Capsules for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Solanezumab for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)7
Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) for spinal muscular atrophies of childhoodTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Supermicrosurgical Lymphaticovenular Anastomosis (LVA) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
tACS combined with 40 Hz sound stimulation for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tavapadon for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Tersolisib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TEV-56286 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
The LFP Beta aDBS System for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Tominersen for huntington diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Transcranial alternating current stimulation for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
transcranial magnetic resonance guided focused ultrasound BBB disruption for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
tributyrin for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Troculeucel for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trontinemab for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Valacyclovir for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Valiltramiprosate for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
VCA-894A for charcot-marie-tooth diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Votoplam (blinded) for huntington diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Wujia Yizhi granules for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Xanomeline Enteric Capsule + Xanomeline/Trospium Chloride Capsule for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
YA-101 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1